Potential impact of host immunity on malaria treatment outcome in Tanzanian children infected with *Plasmodium falciparum*

Anders Enevold*1, Watoky MMM Nkya2, Michael Theisen3, Lasse S Vestergaard1,4, Anja TR Jensen1, Trine Staalsoe1, Thor G Theander1, Ib C Bygbjerg1 and Michael Alifrangis1

Address: 1Centre for Medical Parasitology, Institute of International Health, Immunology and Microbiology, University of Copenhagen, Copenhagen, Denmark, 2Mbeya Referral Hospital (MRH), Mbeya, Tanzania, 3Department of Infectious Disease Immunology, Statens Serum Institute, Copenhagen, Denmark and 4Department of Epidemiology, Statens Serum Institute, Copenhagen, Denmark

Email: Anders Enevold* - enevold@cmp.dk; Watoky MMM Nkya - mmmnkya@yahoo.com; Michael Theisen - mth@ssi.dk; Lasse S Vestergaard - lav@ssi.dk; Anja TR Jensen - atrj@cmp.dk; Trine Staalsoe - staalsoe@cmp.dk; Thor G Theander - Theander@cmp.dk; Ib C Bygbjerg - I.bygbjerg@pubhealth.ku.dk; Michael Alifrangis - alifrangis@cmp.dk

* Corresponding author

Abstract

**Background:** In malaria endemic areas children may recover from malaria after chemotherapy in spite of harbouring genotypically drug-resistant *Plasmodium falciparum*. This phenomenon suggests that there is a synergy between drug treatment and acquired immunity. This hypothesis was examined in an area of moderately intense transmission of *P. falciparum* in Tanzania during a drug trial with sulphadoxine-pyrimethamine (SP) or amodiaquine (AQ).

**Methods:** One hundred children with uncomplicated malaria were treated with either SP or AQ and followed for 28 days. Mutations in parasite genes related to SP and AQ-resistance as well as human sickle cell trait and alpha-thalassaemia were determined using PCR and sequence-specific oligonucleotide probes and enzyme-linked immunosorbent assay (SSOP-ELISA), and IgG antibody responses to a panel of *P. falciparum* antigens were assessed and related to treatment outcome.

**Results:** Parasitological or clinical treatment failure (TF) was observed in 68% and 38% of children receiving SP or AQ, respectively. In those with adequate clinical and parasitological response (ACPR) compared to children with TF, and for both treatment regimens, prevalence and levels of anti-Glutamate-rich Protein (GLURP)-specific IgG antibodies were significantly higher (P < 0.001), while prevalence of parasite haplotypes associated with SP and AQ resistance was lower (P = 0.02 and P = 0.07, respectively). Interestingly, anti-GLURP-IgG antibodies were more strongly associated with treatment outcome than parasite resistant haplotypes, while the IgG responses to none of the other 11 malaria antigens were not significantly associated with ACPR.

**Conclusion:** These findings suggest that GLURP-specific IgG antibodies in this setting contribute to clearance of drug-resistant infections and support the hypothesis that acquired immunity enhances the clinical efficacy of drug therapy. The results should be confirmed in larger scale with greater sample size and with variation in transmission intensity.
Background

Plasmodium falciparum resistance to commonly available antimalarial drugs such as chloroquine (CQ), amodiaquine (AQ) sulphadoxine-pyrimethamine (SP) is now widespread in most malaria-endemic areas, including Tanzania [1,2]. It has been established that polymorphisms in the parasite dihydrofolate reductase (dhfr), dihydropteroate synthetase (dhps) and chloroquine resistance transporter (Pfcrt) genes are associated with SP and CQ resistance, respectively in vitro [3,4]. Point mutations at positions N51I, C59R and S108N in the dhps gene [5,6] and at positions A437G and K540E in the dhfr gene [7,8] have shown to predict a reduced efficacy to SP in vivo. Likewise, the K76T mutation in the Pfcrt gene is a well described predictor of reduced parasite susceptibility to CQ [9], and to a lesser extent AQ [10]. The prevalence of these mutations has increased as a result of high drug pressure in most sub-Saharan countries in recent years (reviewed in [2,11]).

Patients infected with P. falciparum parasites carrying such drug-resistant mutations sometimes overcome infection after treatment [12]. The ability to recover has been associated with host age [13,14] and transmission intensity [15,16], reflecting an effect of acquired host immunity. From animal models it has also been established that immunity enhances the efficacy of malaria drug treatment [17]. Moreover, haemoglobinopathies, such as sickle cell trait, has been related to increased efficacy of SP treatment of uncomplicated falciparum malaria in Kenya [18]. Therefore, recovery from malaria may depend on the drug efficacy and parasite drug-resistance, as well as a complex interaction with host factors like acquired immunity and innate resistance e.g. haemoglobinopathies.

Various studies have investigated the relationship between potential immune mechanisms, such as antibody responses, and therapeutic efficacy. It has been demonstrated that increased amounts of anti-RESA and anti-NANP antibodies in patients treated with CQ were associated with better clearance of resistant parasites [19,20], whereas other studies could not establish evidence for elevated anti-MSP1 and anti-AMA1 antibody levels in patients recovering after treatment with CQ, SP or AQ [21-23]. These observations are however difficult to compare, when factors like patient age, innate resistance, intensity of transmission and level of drug resistance vary substantially between these studies and may influence treatment outcome.

The objective of this study was to evaluate factors influencing outcome of antimalarial treatment to uncomplicated P. falciparum malaria, such as acquired immunity, haemoglobinopathies and genotypic markers of drug resistance. The study likewise wanted to investigate the applicability of drug efficacy trails in testing the importance of antibodies to different vaccine-candidates in patients receiving drugs with reduced efficacy, as suggested previously [14,22]. Patients were children below five years of age exposed to low-to-moderate levels of malaria transmission in Tanzania, treated with either SP or AQ for episodes of uncomplicated febrile malaria.

Methods

Study population and samples

The study was done as part of an annual clinical drug-efficacy trial under the East Africa Network for Monitoring Antimalarial Treatment (EANMAT) in collaboration with the National Malaria Control Programme in Tanzania. The trial was conducted during the rainy season between February and July 2005 in Chamwino village, Dodoma region, which is an area characterized by low-to-moderate malaria transmission of mainly P. falciparum. The study protocol was approved by the Ethical Committee of the National Institute for Medical Research and Ministry of Health, Tanzania.

The efficacy study was designed to enrol 100 patients aged 6–59 months presenting with uncomplicated malaria if they met the criteria as defined in the standard efficacy testing protocol by WHO [24]: i) monoinfection with P. falciparum at parasite densities above 2,000/μl and below 200,000/μl, ii) axillary temperature ≥ 37.5°C, iii) haemoglobin > 5 g/dl, iv) absence of severe malnutrition, v) absence of general danger signs, severe and complicated malaria, and vi) informed written consent from parents/guardians.

Patients were randomly allocated to receive either sulphadoxine-pyrimethamine (SP) (25 mg/kg sulphadoxine and 1.25 mg/kg pyrimethamine) as a single dose (Fansidar®, Roche, Switzerland) or amodiaquine (AQ) (10 mg/kg), once daily for three days (Pfizer, Senegal). Patients were followed up clinically and parasitologically on days 0, 1, 2, 3, 7, 14, and 28 and on any other day if the patient felt unwell.

Treatment outcome during 28 days of follow-up were classified as early treatment failure (ETF), late clinical failure (LCF), late parasitological failure (LPF) or adequate clinical and parasitological response (ACPR) according to the standard protocol of WHO [24]. For the purpose of this study, patients with ETF, LCF and LPF were grouped as treatment failures (TF). LPF were defined as patients with presence of parasitaemia on any day from day 7 to day 28 and axillary temperature < 37.5°C without previously having ETF or LCF. Patients failing treatment or with signs of severe malaria were given quinine and referred to the nearby district hospital.
Parasitaemia was determined microscopically using thin smear of fingerprick blood and stained with 3% Giemsa. Packed cell volume (PCV) was measured in haematocrit capillary tubes. Plasma samples were collected upon centrifugation, and stored at minus 20°C until further analysis.

**DNA and genetic analysis**

DNA was extracted from fingerprick blood collected on filter paper, as previously described [25]. Nested polymerase chain reaction (PCR) assays were applied to differentiate recrudescence from new infections by comparing PCR-generated *msp2* genotype patterns in regions FC27 and IC-1 from samples collected on day 0, 7, 14 and 28 [26]. Analysis of the *msp2* genotypes was done according to Cattamanchi *et al* [27]: An outcome was defined as recrudescence if a subsequent sample on any day from day 7 to day 28 post-treatment contained identical alleles or a subset of the alleles present in the day 0 sample and the patient were classified as having late parasitological treatment failure (LPF). An outcome was defined as re-infection if a subsequent sample on any day from day 7 to day 28 post-treatment contained only new alleles compared to the day 0 sample and the patient were classified as having an adequate clinical and parasitological response (ACPR) [24].

*Plasmodium falciparum* single nucleotide polymorphisms (SNPs) at *dhfr* (position 50/51, 59 and 108), *dhps* (position 436/437, 540, 581 and 613) and *Pfcrtd* (position 72–76) were determined on day 0 by sequence-specific oligonucleotide probes (SSOP) and Enzyme-Linked ImmunoSorbert Assay (ELISA)-based technique of PCR amplified fragments as described in [27] Briefly, biotin-conjugated nested PCR amplified DNA were fixed on streptavidin-coated ELISA plates and mixed with digoxigenin-labelled oligonucleotide probes with specificity for the SNPs of interest. The mixtures were washed with high stringency at set temperatures before incubated with peroxidase-conjugated anti-digoxigenin antibodies and visualized by o-phenylene-diamine (OPD). The SSOP's enables detection of mixed haplotypes with high specificity. The SNP’s were constructed into haplotypes. Infections with mixed parasite haplotypes were only classified as 'mixed' when none of the polymorphisms in the same codon were dominant as determined by OD values of differences above 50%. Sickle cell trait were detected by screening the human β-haemoglobin gene for the A18T mutation by SSOP-ELISA [28] and the African alpha^{3,7} deletion variant of alpha-thalassaemia was determined as previously described [29].

**Recombinant *P. falciparum* antigens and synthetic peptides**

The *P. falciparum* antigens used in the present study were: the N-terminal non-repeat R0 domain of the Glutamate-rich Protein (GLURP-R0) (amino acids 27–500, FVO strain) [30]; the C-terminal GLURP-R2 repeat region (amino acids 705–1178, F32 strain) [31]; the synthetic peptide corresponding to the repeat region (NANPx6) of the circumsporozoite protein (CSP); the EBA-4 peptide of the Erythrocyte Binding Antigen-175 (EBA-175) [32]; the N-terminal region of the Apical Membrane Protein 1 (AMA1) (amino acids 25 to 545, FVO strain) with mutated glycosylation sites [33]; the non-polymorphic C-terminal region of the Merozoite Surface Protein 3 (MSP3) (amino acids 212–380, FVO strain) [30]; the 19 kDa fragment of Merozoite Surface Protein 1 (MSP1) [34]; three PfEMP1 recombinant HIS-tagged proteins: The CDR1-α and DBL4-γ-DBL5-δ domains of the PFD1235w and the DBL2-β domain of the PF13_0003 [35,36]; and crude extract of schizont material [37].

**Antibody levels estimated by ELISA**

The plasma samples collected at day 0 were tested for the presence of IgG to the eleven antigens mentioned above by ELISA as previously described [35]. Wells of Maxisorp microtiter plates (Nunc, Roskilde, Denmark) were coated with 100 μl of the recombinant protein diluted in 0.1 M glycine-HCl (pH 2.75) (apart from CSP that was diluted in phosphate-buffered saline [PBS], pH 7.2) by overnight incubation at 4°C. Plasma collected from 30 residents of a Tanzanian village where malaria is holoendemic were used as a reference positive plasma pool and plasma from 19 healthy Danish donors who have never been exposed to malaria were used as negative controls. To account for day-to-day variation between assays, antibody responses were calculated as arbitrary units (AU) with the following formula: 

\[
\text{[(OD}_{\text{sample plasma}} - \text{OD}_{\text{background}})/(\text{OD}_{\text{positive plasma}} - \text{OD}_{\text{background}})] \times 100
\]

The cut-off for a positive antibody response was defined as the mean level plus two standard deviations of the antibody reactivity among the negative controls.

**Measurement of VSA-specific IgG by flow cytometry**

Plasma levels of IgG with specificity for variant surface antigens (VSA) on two parasite isolate lines with different VSA-expression profiles, 3D7 unselected (VSA1) and 3D7 selected on transformed human bone marrow endothelial cells (THmEB) (VSA2) [35] were tested by a flow cytometric assay previously described [38]. Plasma from six residents of a holoendemic Ghanaian village and six Danish donors served as positive and negative controls, respectively. For each plasma sample, the mean fluorescence index (MFI) was recorded and used as a measure of the VSA-specific antibody level. Antibody responses were calculated as arbitrary units (AU) with the following for-
mula: \[ \frac{(\text{MFI}_{\text{sample plasma}} - \text{MFI}_{\text{background}})}{(\text{MFI}_{\text{positive plasma}} - \text{MFI}_{\text{background}})} \times 100 \]. The antibody positivity cut-off was determined as the mean antibody levels of the plasma from the mean of the six Danish donors plus two standard deviations.

Statistics
Statistical analyses of data were performed with Stata/SE version 8.2 (Stata Corp., Texas, US). \( \chi^2 \) test and Fisher’s exact test were used to compare differences in proportions of antibody responders, presence of parasite resistant genotypes and genes assessing haemoglobinopathies in patients with adequate clinical and parasitological response (ACPR) and treatment failure (TF). Non-parametric Mann Whitney rank sum test was used to analyse differences in median antibody levels between treatment groups. Associations between quantitative variables as age, parasite densities and haemoglobin levels were assessed by linear regression. For multivariable analysis, logistic regression models were used to assess predictors of treatment failure. In these models, parasite density (log parasite density pre-treatment), age and age-squared were used as continuous exposure variables, while presence or absence of parasite resistant genotypes, human antibodies and genes causing haemoglobinopathies were included as categorical exposure variables. Possible effect modification between the exposure variables was considered by testing for interaction between presence of parasite mutant haplotypes and IgG antibodies. \( P < 0.05 \) was defined as significant.

Results
Characteristics of the study groups and outcome of treatment
The baseline characteristics of the 100 patients enrolled in the study are shown in Table 1. Age, sex, parasitaemia, temperature and haemoglobin levels on the day of enrolment were similar in the SP and AQ treatment groups.

| Treatment outcome | SP (n = 50) | AQ (n = 50) |
|-------------------|------------|------------|
| TF                | ACPR       | TF          | ACPR       |
| PCR un-corrected, N (%) | 35 (70)  | 15 (30)  | 22 (44)  | 28 (56)  |
| PCR corrected, N (%)  | 34 (68)  | 16 (32)  | 19 (38)  | 31 (62)  |
| Median age (months, CI) | 31.5 (25.3–36) | 27.5 (19–41.4) | 24 (19.4–43.9) | 32 (23.5–38.5) |
| Females (%)         | 31.6      | 38.7      | 41.2      | 68.7      |
| Geometric mean parasite density, day 0 (/ul. CI) | 39.810 (28.184–56.234)* | 17.865 (8.511–37.153) | 28.840 (14.256–57.544) | 32.359 (22.387–43.651) |
| Mean haemoglobin day 0 (PCV, SD) | 29.4 (4.8) | 29.6 (5.8) | 28.6 (6.5) | 30.7 (5.1) |
| Mean temperature day 0 (°C, SD) | 38.8 (0.9) | 38.5 (0.6) | 38.5 (0.9) | 39.1 (0.8) |
| Alpha+-thalassaemia, % | 33.4      | 27.6      | 42.9      | 35.7      |
| HbAS, %             | 15.2      | 12.5      | 10.4      | 9.7       |

TF: Parasitological or clinical treatment failure, ACPR: Adequate clinical and parasitological response. SP: sulphasoxine-pyrimethamine, AQ: amodiaquine. * Significantly different from value for parasite density in ACPR group as calculated by Student’s t test.

Of the 50 patients receiving SP, none presented with early clinical failure (ECF), three patients presented with late clinical failures (LCF). 31 patients presented with late parasitological failures (LPF) and the remaining 16 patients had an adequate clinical and parasitological response (ACPR). Of the 50 patients receiving AQ, one presented with ECF, two patients presented with LCF, 16 patients presented with LPF and the remaining 31 patients had an ACPR. All samples were adjusted for new infections by PCR genotyping. Before PCR corrections, 32 patients receiving SP and 22 patients receiving AQ presented with LPF, respectively. All patients with either ECR, LCF or LPF were grouped together as treatment failures (TF). Thus, the treatment failure rates were 68% in the SP group and 38% in the AQ group. There were no significant differences with respect to age, sex, temperature, and haemoglobin level between patients with ACPR or TF in any of the treatment groups. However, in patients receiving SP, the parasite density on day 0 was higher in the TF than ACPR group (\( P = 0.03 \)). Levels of haemoglobin, parasite density and failure rates showed no relation to age (data not shown).

Associations between parasite mutant haplotypes and treatment outcome
The haplotypes based on the single nucleotide polymorphisms at codon 50/51, 59 and 108 of the \( P. falciparum \) \( dhfr \) gene, and codon 436/437, 540, 581 and 613 of the \( P. falciparum \) \( dhps \) gene, were determined on day 0 for parasite infections in patients receiving SP (Table 2).

A higher prevalence of the triple mutant haplotype, CIRN in \( dhfr \), was observed in patients experiencing TF (82%) compared to patients with ACPR (50%), \( \chi^2 = 5.6, P = \ldots \)
0.02). There was no significant association between \textit{dhps} mutant haplotypes (single SGKAA and double SGEAA combined) and treatment outcome ($\chi^2 = 1.8$, P = 0.18), nor between the quintuple \textit{dhfr-dhps} mutant haplotype (CIRN-SGEAA) and TF ($\chi^2 = 0.6$, P = 0.46). However, due to the low number of samples, we could not exclude a possible association between the quintuple mutant haplotype and treatment outcome.

The majority of parasites in patients receiving AQ expressed the \textit{Pfcrt} mutant haplotype CVIET (68%) and the remaining samples were the CVMNK wildtype haplotype. There was a trend towards higher prevalence of the CVIET haplotype in patients failing AQ treatment (84%) compared to patients with ACPR (58%), although not statistically significant ($\chi^2 = 3.2$, P = 0.08).

Thus, a higher prevalence of parasites expressing triple mutant \textit{dhfr} haplotype in patients failing SP treatment and a tendency for a higher prevalence of the mutant CVIET haplotype in patients failing AQ treatment were observed, indicating some association between presence of parasite resistant genotypes and treatment outcome.

### Associations between anti-malaria antibodies and treatment outcome

Prevalence and levels of IgG antibodies with specificity for the eleven malaria antigens and the surface of the two parasite isolates were measured on day 0 in patients treated with SP or AQ (Figure 1 and Table 3). In univariate analysis, patients with ACPR had a higher prevalence of anti-GLURP-R0 IgG ($\chi^2 = 20.9$, P < 0.001) and anti-GLURP-R2 IgG ($\chi^2 = 12.7$, P < 0.001) as well as higher levels of anti-GLURP-R0 and R2 IgG (P < 0.001) compared to patients with TF. Such statistically significant associations were not observed for any of the other antigen-specific IgG responses. Furthermore, the associations between ACPR and prevalence and levels of GLURP-R0 and R2 antibodies were significant when the SP and AQ groups were analysed separately ([SP]: R0: $\chi^2 = 11.8$, P = 0.001; R2: $\chi^2 = 9.4$, P = 0.002. [AQ]: R0: $\chi^2 = 11.3$, P = 0.001; R2: $\chi^2 = 3.3$, P = 0.07). The prevalence of the combined IgG responses to GLURP-R0 and R2 was also correlated to ACPR in both the SP ($\chi^2 = 10.1$, P = 0.002) and the AQ ($\chi^2 = 11.3$, P = 0.001) group. By contrast, no association between antibody responses to any other antigen, analysed individually or in combination, and treatment outcome in neither the SP nor the AQ group was demonstrated. Approximately 25% of patients with IgG against GLURP R0 did not have IgG against R2 and vice versa, indicating that responding to R0 not necessarily means responding to R2. Thus, among the thirteen IgG specificities, only anti-GLURP-R0 and R2 IgG proved to be associated with ACPR.

### Impact of haemoglobinopathies on anti-malaria antibodies, parasitaemia and treatment outcome

In the study population, the overall frequency of homozygote and heterozygote alpha+-thalassaemia was 38% and the frequency of sickle cell trait (HbAS) 12%. No sickle cell anaemic patients (HbSS) were found. The prevalence of these traits was similar in the two treatment outcome groups for both SP and AQ (see Table 1). Prevalence and levels of antibodies did not differ between patients with and without sickle cell trait or with and without alpha+-thalassaemia for any of the malaria antigens. A lower parasite density was observed at enrolment in patients with alpha+-thalassaemia receiving AQ (P = 0.007), but not for SP (P = 0.41).
Patients were divided into four groups based on infections with or without mutant haplotypes (the \textit{dhfr} triple mutant haplotype in the SP group, and the CVIET haplotype in the AQ group), and presence or absence of IgG antibodies to each antigen. In Table 4, only data for GLURP-R0 and R2 are shown.

As expected, patients with anti-GLURP IgG infected with a sensitive haplotype (group 1) were more likely to have ACPR compared to patients with no anti-GLURP IgG infected with a resistant parasite haplotype (group 4). Interestingly, there was a marked positive effect of having anti-GLURP IgG on treatment outcome in patients with resistant haplotypes (comparing group 3 vs. 4 for GLURP-R0; [SP]: R0, \( P = 0.004 \) and [AQ]: R0, \( P = 0.02 \)), indicating that possessions of anti-GLURP IgG were associated with reduced risk of TF when infected with resistant parasites. Similar significant associations were seen for GLURP-R2 but not for any of the other antigens.

In multivariate regression models, the effect of IgG antibodies, parasite haplotype and parasite density on treatment outcome was analysed (Table 5). Regardless of parasite density and age, anti-GLURP IgG were the strongest predictor of treatment outcome in the SP and AQ groups separately and combined. Presence of resistant parasite haplotypes and high parasitaemia were also associated with treatment failure in patients receiving SP, but not as strongly as the presence of GLURP-R0 and R2 IgG and not in the AQ group.

### Discussion
This study evaluated the contribution of some anti-malaria antibodies and parasite resistant haplotypes on the outcome of SP and AQ treatment of patients under five years of age with uncomplicated malaria. The rate of SP treatment failure observed (68%) is unexpectedly high for this area of endemity, but similar SP failure rates (43%–74%) have been shown in other parts of Tanzania the last 10 years [39-41]. Not surprisingly patients failing SP and AQ treatment were generally infected with parasites expressing drug resistance-related mutations. However, increased risk of SP treatment failure was associated with the triple \textit{dhfr} (CIRN) irrespective of the \textit{dhps} haplotype status as demonstrated in other studies [5,42].
Interestingly, the prevalence and level of anti-GLURP antibodies was associated with a substantial decreased risk of treatment failure irrespective of drug regimen. This association could not be demonstrated for any of the other antigens studied, neither individually nor combined. Similarly, although there was an association between parasite density and patients failing SP treatment, the treatment outcome was independent of age, alpha-thalassaemia (homozygote or heterozygote) and sickle cell trait, and for AQ treatment outcome, also parasite density. Furthermore, in regression analysis, the presence of GLURP R0 or R2 specific IgG antibodies influenced the risk for failing SP and AQ treatment more strongly than presence of parasite resistant haplotypes.

It has recently been proposed that therapeutic responses to resistant malaria infections can provide a mechanism for measuring effective clinical immunity [14], i.e. drug trials can be useful in identifying antigens and vaccine candidates affording protection [22]. Investigations of the impact of immunity on treatment outcome have however resulted in conflicting findings [19-23]. In line with the observations from the present study, level of anti-IgG to MSP119 was not associated with CQ [22] SP [23] or AQ [21,23] treatment outcome, and prevalence of anti-AMA1 [22] and anti-MSP3 [19] IgG was not associated with reduced risk for CQ treatment failure. However, in contrast to the findings from the present study, the prevalence of IgG to MSP119 was higher in patients clinically recovering after CQ treatment [22], and IgG reactivity to multiple, but not single, K1 and MAD20 alleles of MSP1 were related to efficacy of AQ treatment [21]. In addition, prevalence of anti-NANP and anti-RESA IgG has been demonstrated to be higher in patients recovering successfully from CQ [19] and artesunate [20] treatment. The inability to demonstrate an association between prevalence and levels of antibodies against antigens other than GLURP in AQ treatment group, only a trend towards an increased risk of treatment failure was found in patients infected with the PfcrtdCVIET mutant haplotype. Although the latter could be explained by involvement of other putative genes related to AQ resistance, such as Pfmdr [43], and that the assumptions are based on a relatively small sample size, these findings indicate that the association between parasite resistant genotypes and SP or AQ treatment outcome is not absolute.

Table 3: Level of IgG antibodies in patients to different malaria antigens in relation to treatment outcome.

| Antigen | TF, n = 53 | ACPR, n = 47 | P-value |
|---------|-----------|--------------|----------|
| GLURP-R0 | 0.0 (0.0–1.3) | 8.4 (0.0–47.7) | < 0.001 |
| GLURP-R2 | 0.0 (0.0–5.0) | 7.7 (0.0–49.8) | < 0.001 |
| AMA-1 | 24.3 (0.0–51.1) | 24.5 (0.0–87.3) | 0.25 |
| CSP | 5.8 (0.0–17.1) | 10.2 (0.0–24.4) | 0.42 |
| CDR1α | 15.4 (3.3–61.7) | 9.1 (0.0–30.2) | 0.24 |
| DBL2α | 22.5 (6.9–45.6) | 16.9 (3.4–58.3) | 0.92 |
| DBL4γ-DBL5δ | 10.4 (1.6–38.6) | 12.4 (3.0–44.0) | 0.74 |
| MSP-1 | 80.0 (67.1–144.4) | 122.7 (29.3–162.0) | 0.11 |
| MSP-3 | 5.3 (1.1–12.6) | 8.0 (2.5–18.9) | 0.30 |
| VSA1 | 15.5 (5.2–33.0) | 19.8 (6.1–41.0) | 0.58 |
| VSA2 | 16.3 (4.1–30.9) | 21.1 (7.6–38.7) | 0.21 |
| EBA-175 | 4.3 (0.0–14.1) | 5.9 (0.0–21.0) | 0.54 |
| SCHIZONT | 30.0 (12.9–51.0) | 35.2 (11.1–80.2) | 0.17 |

TF: Parasitological or clinical treatment failure, ACPR: Adequate clinical and parasitological response. Patients receiving sulphadoxine-pyrimethamine (SP) or amodiaquine (AQ) are grouped together.

Table 4: Associations between presence of IgG antibodies to GLURP-R0 + R2 and parasite haplotypes in relation to treatment outcome.

| Treatment and group | Presence of antibody/ resistant haplotype | TF | ACPR | TF | ACPR |
|---------------------|------------------------------------------|----|------|----|------|
| SP                  | -/+, 1                                  | 2  | 4    | 1  | 6    |
|                     | +/-, 2                                  | 4  | 3    | 5  | 2    |
|                     | +/+ , 3                                  | 6  | 7    | 9  | 7    |
|                     | +/-, 4                                  | 22 | 2    | 19 | 1    |
| AQ                  | -/+, 1                                  | 1  | 7    | 0  | 8    |
|                     | +/-, 2                                  | 2  | 5    | 3  | 4    |
|                     | +/- , 3                                  | 4  | 12   | 3  | 11   |
|                     | +/-, 4                                  | 12 | 6    | 13 | 7    |

TF: Parasitological or clinical treatment failure, ACPR: Adequate clinical and parasitological response. SP: sulphadoxine-pyrimethamine, AQ: amodiaquine. A number of patients with presence (+) or absence (-) of IgG antibodies to GLURP-R0 or R2 combined with resistant (+) or sensitive (-) genotypes associated with treatment outcome. Haplotypes were defined as resistant if parasites expressed the dhfr triple haplotype (CIRN) for the SP group or the CVIET haplotype for the AQ group.
the present study may be explained by the relatively small sample size (50 patients in each group); alternatively by allelic diversity as shown in the study from Gabon [20], or by variable IgG subclass composition of the patient sera. For instance, it has previously been described that only IgG3 against MSP3 is associated with protection against clinical malaria [44], although this was not observed in another study where total IgG was a strong predictor of protection [45]. Finally, one could speculate if prevalence or level of IgG antibodies to these other specific antigens are not primary responsible for, or associated with, host immune protection against uncomplicated malaria but rather severe malaria – which none of the patients had. However, in patients with established clinical malaria, sporozoite-blocking anti-CSP antibodies were, however, not expected to influence treatment outcome.

Interestingly, at day 0, all patients had IgG antibodies to at least one of the antigens tested, but no patient had IgG antibodies to all the antigens. This may reflect substantial variation in response to infections. Previous immunological studies have demonstrated that GLURP-specific IgG antibodies are associated with protection against high parasitaemia [46], clinical disease [47] and inhibition of parasite growth in vitro [48], but this is not direct evidence of IgG antibodies against GLURP. However, it was shown that patients clinically recovering after treatment are more likely to carry anti-GLURP IgG antibodies and the presence of such antibodies were associated with reduced risk of failing drug-resistant parasite infections.

Conclusion
This study suggests that presence or level of GLURP-specific IgG antibodies in some settings are better predictors of SP and AQ treatment outcome than the parasite density at enrolment and drug-resistant related parasite mutations. This confirms the hypothesis that acquired immunity enhances the efficacy of antimalarial treatment, and supports the use of drug trials to identify markers of immunological importance. In addition, the findings suggest that drugs with reduced efficacy, such as SP, may still be effective for treatment of uncomplicated malaria in individuals with some acquired immunity, such as older children and adults living in areas of intense malaria transmission.

Authors’ contributions
AE, LV, MT and MA conceived and designed the study. WN was responsible for the clinical trial and the supervision of patient enrolment and sample collection. AE performed the experiments and analysis with MA, MT, IB and LV. TS, AJ, IB and TT participated in manuscript preparation and design of the study. All authors read and approved the final manuscript.

Acknowledgements
The study was funded by the ENRECA, grant number 104.Dan.B.312 and the National Malaria Control Programme, Ministry of Health, Tanzania. AE is supported by DANIDA, grant number 91203.

The study was conducted under the auspices of the Joint Malaria Programme, a collaborative research initiative between Centre for Medical Parasitology at the University of Copenhagen, Kilimanjaro Christian Medical College, London School of Hygiene and Tropical Medicine and the Tanzania National Institute for Medical Research. We highly appreciate Dr Mutabingwa’s clinical contributions and the help of technicians, nurses and clinical officers at the Chamwino Health Center in conducting the clinical trial and collecting the samples. We thank Kai Olsen for excellent technical
laboratory assistance as well as Dr. Ed Remarque, Institute Pasteur, Paris, for providing the AMA-1 antigen and Dr. Giampietro Corradin, University of Lausanne, Switzerland, for providing the CSP synthetic peptide.

References

1. Rapuoda B, Ali A, Bakyaita N, Mutabingwa TK, Mwiwa A, Wraagando C, Mugisha V, Stadsko M, Snow RW, Watkins WM: The efficacy of antimalarial monotherapies, sulfadoxine-pyrimethamine and amodiaquine in East Africa: implications for sub-regional policy. Trop Med Int Health 2003, 8:860-867.

2. Wangrichanala C, Pickard AL, Wernsdorfer WH, Meshnick SR: Epidemiology of drug-resistant malaria. Lancet Infect Dis 2002, 2:279-289.

3. Fidock DA, Nomura T, Talley AK, Cooper RA, Dzekunov SM, Ferdig MT, Ursos LMB, Sidhu ABS, Naude B, Deitsch KW: Mutations in the P falciparum digestive vacuole transmembrane protein PFCRT and evidence for their role in chloroquine resistance. Cell 2000, 101:661-71.

4. Ploew CV, Cortese JF, Dijimde EM, Nyanwayou OC, Watkins WM, Winstanley PA, Estrada-Frago JG, Mollinedo RE, Avila JC, Cespedes JL: Mutations in Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase and epidemiologic patterns of pyrimethamine-sulfadoxine use and resistance. J Infect Dis 1997, 176:1590-1596.

5. Basco LK, Tahr T, Keundjian A, Ringwald P: Sequence variations in the genes encoding dihydropteroate synthase and dihydrofolate reductase and clinical response to sulfadoxine-pyrimethamine among Cambodian children with uncomplicated falciparum malaria. J Infect Dis 2000, 182:624-628.

6. Nizia AM, Nduati E, Mberu EK, Sibley CH, Monks SA, Winstanley PA, Watkins WM: Molecular evidence of greater selective pressure for drug resistance exerted by the long-acting antifolate pyrimethamine/sulfadoxine compared with the shorter-acting chlorproguanil/dapsone on Kenyan Plasmodium falciparum. J Infect Dis 2000, 181:2023-2028.

7. Kublin JG, Dznjalamala FK, Kanwendo DD, Malkin EM, Cortese JF, Martin LG, Mukadom RAM, Rogerson SJ, Lescano AG, Molyneux ME: Molecular markers for failure of sulfadoxine-pyrimethamine and chlorproguanil/dapsone treatment of Plasmodium falciparum malaria. J Infect Dis 2002, 185:380-388.

8. Kyabayinze D, Cattamanchi A, Kamya MR, Rosenthal PJ, Dorsey G: Validation of a simplified method for using molecular markers to predict sulfadoxine-pyrimethamine treatment failure in African children with falciparum malaria. Am J Trop Med Hyg 2003, 69:247-252.

9. Wellens TE, Ploew CV: Chloroquine-resistant malaria. J Infect Dis 2001, 184:660-776.

10. Ochong EO, Van den Broek IVF, Keus K, Nizia A: Short report: Association between chloroquine and amodiaquine resistance and allelic variation in the Plasmodium falciparum multi- drug resistance 1 gene and the chloroquine resistance transporter gene in isolates from the upper Nile in southern Sudan. Am J Trop Med Hyg 2003, 69:184-187.

11. Wernsdorfer WH, Noed H: Molecular markers for drug resistance in malaria: use in treatment, diagnosis and epidemiology. Curr Open Infect Dis 2003, 6:553-558.

12. Dorsey G, Kamya MR, Singh A, Rosenthal PJ: Polymorphisms in the Plasmodium falciparum pfcrt and pfmdr-1 genes and clinical response to chloroquine in Kampala, Uganda. J Infect Dis 2001, 183:1417-1420.

13. Omar SA, Adagu G, Verhurst DC: Can pretreatment screening for dhps and dhfr point mutations in Plasmodium falciparum infections be used to predict sulfadoxine-pyrimethamine treatment failure? Trans R Soc Trop Med Hyg 2001, 95:315-319.

14. Dijimde EM, Doumo OK, Traore O, Guindo AB, Kayentao K, Diouf Y, Niane-Doumbo S, Coulibaly D, Kane AK, Cissoko Y, et al.: Cleavage of host-resistance markers as a model for protective immunity in Plasmodium falciparum malaria. Am J Trop Med Hyg 2003, 69:558-563.

15. Khalil IF, Alfrangis M, Tarimo DS, Staloos T, Satti GMH, Theander TG, Ronn AM, Bygbjerg IC: The roles of the pfcrt 76T and pfmdr1 86Y mutations, immunity and the initial level of parasitaemia in predicting the outcome of chloroquine treatment in two areas with different transmission intensities. Ann Trop Med Parasitol 2005, 99:441-448.

16. Francis D, Nsobya SL, Talisuna A, Yeka A, Kamya MR, Macheke R, Dokomajilar C, Rosenthal PJ, Dorsey G: Geographic differences in antimalarial drug efficacy in Uganda are explained by differences in endemcity and not by known molecular markers of drug resistance. J Infect Dis 2006, 193:978-986.

17. Targett GAT: Malaria – Drug-Use and the Immune-Response. Parasitology 1992, 105:561-570.

18. Terfoulayou ME, Adayo MA, Udayakumar V, Kolczak MS, Oloj A, Kager PA, Lala AA, Nahlen BL, ter Kulle FO: Increased efficacy of sulfadoxine-pyrimethamine in the treatment of uncomplicated falciparum malaria among children with sickle cell trait in western Kenya. J Infect Dis 2002, 186:1661-1668.

19. Roper V, Roefen WW, Brandt P, Verhave JP, Roussillon C: Anti-NANP antibody and treatment efficacy in patients with acute uncomplicated falciparum malaria attacks. Parasite Immunol 2000, 22:589-593.

20. Mayxay M, Chotivanich K, Pukrittayakamee S, Newton P, Looareesuwan S, White NJ: Contribution of Plasmodium falciparum CSP-specific antibodies to the therapeutic response in falciparum malaria. Am J Trop Med Hyg 2001, 65:918-923.

21. Mawili-Mboumba DP, Borrman S, Cavanagh DR, McBride JS, Matsiegui PB, Missinou MA, Kremser NG, Ntomu F: Antibody responses to Plasmodium falciparum merozoite surface protein-1 and efficacy of amodiaquine in gabanese children with P falciparum malaria. J Infect Dis 2003, 187:1137-1141.

22. Pinder M, Sutherland CJ, Sisay-Joof F, Ismaili J, McCall MB, Ord R, Hallett R, Holder AA, Milligan P: Immunoglobulin G antibodies to merozoite surface antigens are associated with recovery from chloroquine-resistant Plasmodium falciparum in gambian children. Infect Immun 2006, 74:2887-2893.

23. Aubouy A, Migot-Nabias F, Deloron P: Correlations between treatment outcome and both anti-MS1 antibody response and erythrocyte-related genetic factors in Plasmodium falciparum malaria. Infect Genet Evol 2007, 7:147-154.

24. World Health Organization: Assessment and monitoring of antimalarial drug efficacy for the treatment of uncomplicated falciparum malaria. WHO: Genve 2003.

25. Pearce RJ, Drakeley C, Chandramohan D, Moshia F, Roger C: Molecular determination of point mutation haplotypes in the dihydrofolate reductase and dihydropterotate synthase of Plasmodium falciparum in three districts of northern Tanzania. Antimicrob Agents Chemother 2003, 47:1347-1354.

26. Snounou G, Zhu XP, Sirinoo N, Jarra W, Thaithong S, Brown KN, Viriyakosol S: Biased distribution of msp1 and msp2 allelic variants in Plasmodium falciparum populations in Thailand. Trans R Soc Trop Med Hyg 1999, 93:369-374.

27. Alfrangis M, Enosse S, Pearce RJ, Drakeley C, Roper V, Khalil IF, Nkya WMMM, Ronn AM, Theander TG, Bygbjerg IC: A simple, high-throughput method to detect Plasmodium falciparum single nucleotide polymorphisms in the dihydrofolate reductase, dihydropterotate synthase, and P. falciparum chloroquine resistance transporter genes using polymerase chain reaction- and enzyme-linked immunosorbent assay-based technology. Am J Trop Med Hyg 2005, 72:155-162.

28. Enevold A, Vestergaard LS, Lusungu J, Drakeley C, Lemnge P, Theander TG, Bygbjerg IC, Alfrangis M: Rapid screening for glucose-6-phosphate dehydrogenase deficiency and haemoglobin polymorphisms in Africa by a simple high-throughput SSOP-ELISA method. Malar J 2005, 4:61.

29. Liu YT, Old JM, Miles K, Fisher CA, Weatherill DJ, Clegg JP: Rapid detection of alpha-thalassaemia deletions and alpha-globin gene triplication by multiplex polymerase chain reactions. Br J Haematol 2000, 108:295-299.

30. Carvalho LJM, Oliveira SG, Theisen M, Alves FA, Andrade MCR, Zan- ini GM, Brígido MCO, Oeuvray C, Povoa MM, Muniz JAPC: Immuni- zation of Saimiri sciureus monkeys with Plasmodium falciparum merozoite surface protein-3 and glutamate-rich protein suggests that protection is related to antibody levels. Scand J Immunol 2004, 59:363-372.

31. Theisen M, Vuust J, Gottschau A, Jepsen S, Hogh B: Antigenicity and Immunogenicity of Recombinant Glutamate-Rich Protein of Plasmodium-Falciparum Expressed in Escherichia-Coli. Clin Diagn Lab Immuno 1995, 2:30-34.

32. Touré FS, Deloron P, Migot-Nabias F: Analysis of Human Anti- bodies to Erythrocyte Binding Antigen 175 Peptide 4 of Plas- modium falciparum. Clin Med Res 2006, 4:1-6.
33. Kocken CHM, Withers-Martinez C, Dubbeld MA, van der Wel A, Hackett F, Blackman MJ, Thomas AW: High-level expression of the malaria blood-stage vaccine candidate Plasmodium falciparum apical membrane antigen 1 and induction of antibodies that inhibit erythrocyte invasion. Infect Immun 2002, 70:4471-4476.

34. Bonnet S, Petres S, Holm I, Fontaine T, Rosario S, Roth C, Longacre S, Soluble and glyco-lipid modified baculovirus Plasmodium falciparum C-terminal merozoite surface protein 1, two forms of a leading malaria vaccine candidate. Vaccine 2006, 24:5997-6008.

35. Jensen ATR, Magistra do P, Sharp S, Joergensen L, Lavstsen T, Chiuciu A, Salanti A, Vestergaard LS, Lusingu JP, Hermsen R: Plasmodium falciparum associated with severe childhood malaria preferentially expresses PfEMP1 encoded by group A var genes. J Exp Med 2004, 199:1179-1190.

36. Joergensen L, Turner L, Magistrado P, Dahlback, MA, Vestergaard LS, Lusingu JP, Lennge M, Salanti A, Theander TG, Jensen ATR: Limited cross-reactivity among domains of the Plasmodium falciparum clone 3D7 erythrocyte membrane protein 1 family. Infect Immun 2006, 74:6778-6784.

37. Hogh B, Marbiah NT, Burghaus PA, Andersen PK: Relationship Between Maternally Derived Anti-Plasmodium Falciparum Antibodies and Risk of Infection and Disease in Infants Living in An Area of Liberia, West-Africa, In Which Malaria Is Highly Endemic. Infect Immun 1995, 63:4034-4038.

38. Staalsoe T, Ghia HA, Dodoo D, Theander TG, Hviid L: Detection of antibodies to variant antigens on Plasmodium falciparum – infected erythrocytes by flow cytometry. Cytometry 1999, 35:329-336.

39. Ronn AM, Msangeni HA, Mhina J, Wernsdorfer WH, Bygbjerg IC: High level of resistance of Plasmodium falciparum to sulfadoxine-pyrimethamine in children in Tanzania. Trans R Soc Trop Med Hyg 1996, 90:179-181.

40. Mutabingwa T, Nzila A, Bheru E, Nduati E, Winstanley P, Hills E, Watkins W: Chlorproguanil-dapsone for treatment of drug-resistant falciparum malaria in Tanzania. Lancet 2001, 358:1718-1723.

41. Mavittu K, Abdulla S, Falk N, Masanja H, Felger I, Mshinda H, Beck HP, Montabingwa T, Nzila A, Mberu E, Nduti E, Winstanley P, Hills E, Winstanley PA, Sibley CH, Watkin WS: Towards an understanding of the mechanism of pyrimethamine-sulfadoxine resistance in Plasmodium falciparum: Genotyping of dihydrofolate reductase and dihydropteroate synthase of Kenyan parasites. Antimicrob Agents Chemother 2000, 44:991-996.

42. Holmgren G, Gil JP, Ferreira PM, Veiga MI, Obonyo CO, Bjorkman A: Antibodies to A Recombinant Glutamate-rich Protein – Evidence for Protection of Individuals Living in A Holoendemic Area of Liberia. J Infect Dis 2004, 190:279-287.

43. Hogh B, Petersen E, Dziegel M, David K, Hanson A, Borre M, Holm I, Vaux J, Jepsen S: Antibodies to A Recombinant Glutamate-Rich Plasmodium-Falciparum Protein – Evidence for Protection of Individuals Living in A Holoendemic Area of Liberia. Am J Trop Med Hyg 1992, 46:307-313.

44. Dodoo D, Theisen M, Kurthzals JAL, Akanmori BD, Koram KA, Jepsen S, Nkrumah FK, Theander TG, Hviid L: Naturally acquired antibodies to the glutamate-rich protein are associated with protection against Plasmodium falciparum malaria. J Infect Dis 2000, 181:1202-1205.

45. Theisen M, Soe S, Oeuvray C, Thomas AW, Vaux J, Danielsen S, Jepsen S, Drulil P: The glutamate-rich protein (GLURP) of Plasmodium falciparum is a target for antibody-dependent monocyte-mediated inhibition of parasite growth in vitro. Infect Immun 1998, 66:11-17.